Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006

Published: 2009-06-10

Articles

State of Art on T-cell Lymphomas: The Epidemiology

R Liang

https://doi.org/10.4081/hmr.v2i13.474

Published: June 10, 2009

171

PDF: 1181
- PDF
State of the Art on T-cell lymphomas: the Pathogenesis

ES Jaffe

https://doi.org/10.4081/hmr.v2i13.475

Published: June 10, 2009

210

PDF: 587
- PDF
Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective

G Gisselbrecht

https://doi.org/10.4081/hmr.v2i13.476

Published: June 10, 2009

167

PDF: 227
- PDF
Management of patients with peripheral T-cell lymphoma

JO Armitage

https://doi.org/10.4081/hmr.v2i13.477

Published: June 10, 2009

185

PDF: 254
- PDF
Conventional treatment of peripheral T-cell lymphoma: the Asian perspective

K Tobinai

https://doi.org/10.4081/hmr.v2i13.478

Published: June 10, 2009

172

PDF: 397
- PDF
T-cell lymphoma - standard treatment: The Mexican experience

A Avilès

https://doi.org/10.4081/hmr.v2i13.479

Published: June 10, 2009

179

PDF: 320
- PDF
Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations

T Rüdiger

https://doi.org/10.4081/hmr.v2i13.480

Published: June 10, 2009

194

PDF: 197
- PDF
Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfrα deregulation

SA Pileri, PP Piccaluga, C Agostinelli, S Zupo, A Carbone, F Facchetti, B Falini, M Ferrarini

https://doi.org/10.4081/hmr.v2i13.481

Published: June 10, 2009

185

PDF: 217
- PDF
Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

RL Piekarz, R Frye, M Turner, J Turner, S Allen, MH Kirschbaum, J Zain, M Prince

https://doi.org/10.4081/hmr.v2i13.482

Published: June 10, 2009

211

PDF: 297
- PDF
Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

SJ Proctor, J Wilkinson

https://doi.org/10.4081/hmr.v2i13.483

Published: June 10, 2009

229

PDF: 1199
- PDF
Forodesine – Preclinical Studies

V Gandhi

https://doi.org/10.4081/hmr.v2i13.484

Published: June 10, 2009

162

PDF: 551
- PDF
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v2i13.485

Published: June 10, 2009

255

PDF: 236
- PDF
Nelarabine – A New Age in the Management of Lymphoid Malignancies

MJ Keating

https://doi.org/10.4081/hmr.v2i13.486

Published: June 10, 2009

217

PDF: 228
- PDF
New drugs for peripheral T-cell lymphomas

BD Cheson

https://doi.org/10.4081/hmr.v2i13.487

Published: June 10, 2009

193

PDF: 293
- PDF
Cutaneous T-cell lymphomas: histology

M Santucci

https://doi.org/10.4081/hmr.v2i13.488

Published: June 10, 2009

157

PDF: 151
- PDF
Molecular biology of cutaneous T-cell lymphomas

E Berti, S Gimelli, L Venegoni, V Merlo, R Riboni, O Zuffardi, M Paulli

https://doi.org/10.4081/hmr.v2i13.489

Published: June 10, 2009

177

PDF: 207
- PDF
Alemtuzumab (Campath-1H)

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v2i13.490

Published: June 10, 2009

159

PDF: 232
- PDF
Optimizing denileukin diftitox (Ontak®) therapy

M Duvic

https://doi.org/10.4081/hmr.v2i13.491

Published: June 10, 2009

176

PDF: 729
- PDF
Gemcitabine

M Tani, E Marchi, M Fina

https://doi.org/10.4081/hmr.v2i13.492

Published: June 10, 2009

175

PDF: 168
- PDF
Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects

U Wollina

https://doi.org/10.4081/hmr.v2i13.493

Published: June 10, 2009

154

PDF: 396
- PDF
Interferons in cutaneous T-cell lymphomas

R Dummer, A Cozzio, M Urosevic

https://doi.org/10.4081/hmr.v2i13.494

Published: June 10, 2009

164

PDF: 861
- PDF
Optimizing bexarotene therapy for cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i13.495

Published: June 10, 2009

230

PDF: 714
- PDF
Bortezomib

PL Zinzani

https://doi.org/10.4081/hmr.v2i13.496

Published: June 10, 2009

160

PDF: 190
- PDF
Animal models of T-cell lymphomas

Y-W Lin, PD Aplan

https://doi.org/10.4081/hmr.v2i13.497

Published: June 10, 2009

186

PDF: 1201
- PDF
Rationale for the design of combination therapies that are active in T-cell lymphomas?

W Plunkett

https://doi.org/10.4081/hmr.v2i13.498

Published: June 10, 2009

154

PDF: 150
- PDF
Peripheral T-cell lymphoma: prognostic factors

DD Weisenburger

https://doi.org/10.4081/hmr.v2i13.499

Published: June 10, 2009

160

PDF: 380
- PDF
Prognostic factors in cutaneous T-cell lymphoma

R Willemze

https://doi.org/10.4081/hmr.v2i13.500

Published: June 10, 2009

149

PDF: 853
- PDF
Chemotherapy for peripheral T-cell lymphoma

JM Vose

https://doi.org/10.4081/hmr.v2i13.501

Published: June 10, 2009

152

PDF: 135
- PDF
Chemotherapy in cutaneous T-cell lymphoma

S Rupoli, MG Bernengo, R Alterini, M Cantonetti, PL Zinzani, N Pimpinelli

https://doi.org/10.4081/hmr.v2i13.502

Published: June 10, 2009

186

PDF: 385
- PDF
Autotransplant in peripheral T-cell lymphomas

P Reimer

https://doi.org/10.4081/hmr.v2i13.503

Published: June 10, 2009

141

PDF: 236
- PDF
Relapsed peripheral T-cell non-Hodgkin’s lymphomas: outcome following reduced-intensity conditioning allogeneic stem cell transplantation

P Corradin, A Dodero, L Farina, M Casini, F Narni, F Patriarca, F Benedetti

https://doi.org/10.4081/hmr.v2i13.504

Published: June 10, 2009

189

PDF: 203
- PDF
Auto and allotransplant in cutaneous T-cell lymphomas

F Onida

https://doi.org/10.4081/hmr.v2i13.505

Published: June 10, 2009

166

PDF: 187
- PDF